{"id":4509,"date":"2026-05-18T16:30:56","date_gmt":"2026-05-18T20:30:56","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/"},"modified":"2026-09-24T00:05:29","modified_gmt":"2026-09-24T04:05:29","slug":"gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/","title":{"rendered":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026"},"content":{"rendered":"\n<strong>Paris, France, le 18 mai 2026, 18h30 CEST<\/strong> \u2013 GenSight Biologics (la \u00ab <strong>Soci\u00e9t\u00e9<\/strong> \u00bb) (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, annonce que son Assembl\u00e9e G\u00e9n\u00e9rale Mixte se tiendra demain, mardi 19 mai 2026 \u00e0 14h00 (heure de Paris), et sera retransmise en direct via le lien suivant : <a href=\"https:\/\/gensightbiologics.engagestream.euronext.com\/2026-05-19-ag\/register\">GENSIGHT BIOLOGICS &#8211; Assembl\u00e9e g\u00e9n\u00e9rale 2026<\/a>.\n\n\u00c0 cette occasion, Laurence Rodriguez, Directrice G\u00e9n\u00e9rale, pr\u00e9sentera un bilan des r\u00e9alisations de l\u2019exercice 2025 ainsi que les orientations prioritaires pour l\u2019exercice en cours.\n\n<strong>Faits marquants 2025<\/strong>\n\nL\u2019exercice 2025 a \u00e9t\u00e9 marqu\u00e9 par une s\u00e9rie de financements ayant conduit \u00e0 l\u2019obtention d\u2019une Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) en France ainsi qu\u2019une autorisation d\u00e9rogatoire aux \u00c9tats-Unis en novembre et en Isra\u00ebl en d\u00e9cembre 2025. Ces financements, avec l\u2019entr\u00e9e de nouveaux investisseurs et le soutien d\u2019actionnaires historiques, ont \u00e9galement permis de poursuivre le transfert de technologie de manufacturing et de testing vers de nouveaux partenaires industriels, une \u00e9tape cl\u00e9 dans la s\u00e9curisation de la cha\u00eene d\u2019approvisionnement de GS010 \/ LUMEVOQ<sup>\u00ae<\/sup>.<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>\n\n<strong>Priorit\u00e9s 2026<\/strong>\n\nPour l\u2019exercice 2026, la Direction de GenSight a identifi\u00e9 plusieurs axes strat\u00e9giques qu\u2019elle d\u00e9taillera lors de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale :\n<ul>\n \t<li><strong>Optimisation du rendement de production de GS010 \/ LUMEVOQ<sup>\u00ae<\/sup><\/strong>, afin de renforcer la capacit\u00e9 industrielle et de r\u00e9duire le co\u00fbt de fabrication par lot ;<\/li>\n \t<li><strong>Finalisation du transfert de la strat\u00e9gie de testing<\/strong> en vue de compl\u00e9ter la qualification industrielle ;<\/li>\n \t<li><strong>Financement et lancement du protocole RECOVER<\/strong>, l\u2019essai clinique de Phase III destin\u00e9 \u00e0 d\u00e9montrer l\u2019efficacit\u00e9 de GS010\/LUMEVOQ<sup>\u00ae<\/sup> sur un large nombre de patients atteints de NOHL-<em>ND4<\/em>. Il est rappel\u00e9 que depuis fin mars 2026, les revenus de la Soci\u00e9t\u00e9 couvre ses d\u00e9penses op\u00e9rationnelles ;<\/li>\n \t<li><strong>R\u00e9vision de la strat\u00e9gie de soumission r\u00e9glementaire aupr\u00e8s du MHRA<\/strong> (Medicines and Healthcare products Regulatory Agency, Royaume-Uni), la Soci\u00e9t\u00e9 a d\u00e9cid\u00e9 de r\u00e9\u00e9valuer le calendrier ainsi que sa d\u00e9marche aupr\u00e8s de l\u2019agence britannique \u00e0 la lumi\u00e8re des \u00e9volutions du processus r\u00e9glementaire et de manufacturing.<\/li>\n<\/ul>\n<strong>Modalit\u00e9s de participation \u00e0 l\u2019Assembl\u00e9e G\u00e9n\u00e9rale<\/strong>\n\nL\u2019Assembl\u00e9e G\u00e9n\u00e9rale sera accessible en webcast en direct \u00e0 partir de 14h00 CET via le lien : <a href=\"https:\/\/gensightbiologics.engagestream.euronext.com\/2026-05-19-ag\/register\">GENSIGHT BIOLOGICS &#8211; Assembl\u00e9e g\u00e9n\u00e9rale 2026<\/a>.\n\n<a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> GS010\/LUMEVOQ<sup>\u00ae<\/sup>\u00a0n\u2019a pas encore obtenu d\u2019autorisation de mise sur le march\u00e9 en France ni dans aucun autre pays\u00a0; il n\u2019est donc pas disponible dans le commerce.\n","protected":false},"excerpt":{"rendered":"<ul>\n<li>Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026\u00a0;<\/li>\n<li>Principaux d\u00e9veloppements op\u00e9rationnels de 2025 et 2026.<\/li>\n<\/ul>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[85,79],"news-type":[76,82],"post-year":[],"class_list":["post-4509","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-general-meeting","news-topic-company-and-personnel","news-type-corporate","news-type-general-meeting"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026\u00a0;  Principaux d\u00e9veloppements op\u00e9rationnels de 2025 et 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T20:30:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:29+00:00\" \/>\n<meta name=\"author\" content=\"Arthus Moulin-Fournier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arthus Moulin-Fournier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/\"},\"author\":{\"name\":\"Arthus Moulin-Fournier\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"headline\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026\",\"datePublished\":\"2026-05-18T20:30:56+00:00\",\"dateModified\":\"2026-09-24T04:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/\"},\"wordCount\":463,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/\",\"name\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-05-18T20:30:56+00:00\",\"dateModified\":\"2026-09-24T04:05:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/18\\\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\",\"name\":\"Arthus Moulin-Fournier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"caption\":\"Arthus Moulin-Fournier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics","og_description":"Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026\u00a0;  Principaux d\u00e9veloppements op\u00e9rationnels de 2025 et 2026.","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/","og_site_name":"GenSight Biologics","article_published_time":"2026-05-18T20:30:56+00:00","article_modified_time":"2026-09-24T04:05:29+00:00","author":"Arthus Moulin-Fournier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Arthus Moulin-Fournier","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/"},"author":{"name":"Arthus Moulin-Fournier","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"headline":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026","datePublished":"2026-05-18T20:30:56+00:00","dateModified":"2026-09-24T04:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/"},"wordCount":463,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/","name":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-05-18T20:30:56+00:00","dateModified":"2026-09-24T04:05:29+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/18\/gensight-biologics-tiendra-son-assemblee-generale-mixte-le-19-mai-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Mixte le 19 mai 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18","name":"Arthus Moulin-Fournier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","caption":"Arthus Moulin-Fournier"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4509"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4509"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4509"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4509"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4509"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}